hrs4r
Quiero donar
Firma
LLUÍS RAMIÓ-TORRENTÀ
Posición
Cap de Grup - R4
Jefe de Grupo - R4

Projectes

Codi oficial: SLT017/20/000115 Data inicio:01/07/2021 Data fi: 31/12/2023 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ Organisme finançador: GENERALITAT DE CATALUNYA Ajuda: 74,024.53 €
Codi oficial: RD21/0002/0063 - EM Data inicio:01/01/2022 Data fi: 31/12/2024 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ Organisme finançador: INSTITUTO DE SALUD CARLOS III Ajuda: 136,744.30 €
Codi oficial: Estudio de biomarcadores moleculares neurodegeneración Data inicio:01/01/2022 Data fi: 31/12/2023 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ Organisme finançador: FRANCISCO SORIA MELGUIZO, S.A Ajuda: 325,600 €
Codi oficial: JBTC63KHB Data inicio:11/10/2022 Data fi: 10/07/2023 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER. Ajuda: 20,000 €

Publicacions

Contreras-Rodriguez O, Arnoriaga-Rodríguez M, Miranda-Olivos R, Blasco G, Biarnés C, Puig J, Rivera-Pinto J, Calle ML, Pérez-Brocal V, Moya A, Coll C, Ramió-Torrentà L, Soriano-Mas C, Fernandez-Real JM

Obesity status and obesity-associated gut dysbiosis effects on hypothalamic structural covariance

INTERNATIONAL JOURNAL OF OBESITY, 2022, 46, 30-38 dx.doi.org/10.1038/s41366-021-00953-9

Álvarez Bravo G, Sánchez Cirera L, Angerri Nadal M, Ramió I Torrentà L

Clinical heterogeneity in patients with myoclonus associated to COVID-19

NEUROLOGICAL SCIENCES, 2022, 43, 1587-1592 dx.doi.org/10.1007/s10072-021-05802-1

Mayneris-Perxachs J, Castells-Nobau A, Arnoriaga-Rodríguez M, Garre-Olmo J, Puig J, Ramos R, Martínez-Hernández F, Burokas A, Coll C, Moreno-Navarrete JM, Zapata-Tona C, Pedraza S, Pérez-Brocal V, Ramió-Torrentà L, Ricart W, Moya A, Martínez-García M, Maldonado R, Fernández-Real JM

Caudovirales bacteriophages are associated with improved executive function and memory in flies, mice, and humans

CELL HOST & MICROBE, 2022, 30, 340 dx.doi.org/10.1016/j.chom.2022.01.013

Vermersch P, Brieva-Ruiz L, Fox RJ, Paul F, Ramio-Torrenta L, Schwab M, Moussy A, Mansfield C, Hermine O, Maciejowski M, AB07002 Study Group

Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis A Randomized, Phase 3, Clinical Trial

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2022, 9 dx.doi.org/10.1212/NXI.0000000000001148

Zabalza A, Arrambide G, Otero-Romero S, Pappolla A, Tagliani P, López-Maza S, Cárdenas-Robledo S, Esperalba J, Fernández-Naval C, Martínez-Gallo M, Castillo M, Bonastre M, Resina-Salles M, Bertran J, Rodriguez-Barranco M, Carbonell-Mirabent P, Gonzalez M, Merchan M, Quiroga-Varela A, Miguela A, Gómez I, Álvarez G, Robles R, Perez Del Campo D, Queralt X, Soler MJ, Agraz I, Martinez-Valle F, Rodríguez-Acevedo B, Midaglia L, Vidal-Jordana Á, Cobo-Calvo Á, Tur C, Galan I, Castillo J, Río J, Espejo C, Comabella M, Nos C, Sastre-Garriga J, Ramió-Torrentà L, Tintoré M, Montalban X

Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?

MULTIPLE SCLEROSIS JOURNAL, 2022, 28, 1138-1145 dx.doi.org/10.1177/13524585221089540
0

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives

Cells, 2022, 11 dx.doi.org/10.3390/cells11132058
0

Presence of Blastocystis in gut microbiota is associated with cognitive traits and decreased executive function

ISME JOURNAL, 2022, 16, 2181-2197 dx.doi.org/10.1038/s41396-022-01262-3
0

Gadolinium-enhanced brain lesions in multiple sclerosis relapse.

Neurologia (barcelona, Spain), 2022, 37, 557-563 dx.doi.org/10.1016/j.nrleng.2021.10.005
0

Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.

Neurologia (barcelona, Spain), 2022, 37, 615-630 dx.doi.org/10.1016/j.nrleng.2019.11.001

Formulari de contacte

Conoce el IDIBGI!

menu